CHCWM – Cancer & Hematology Centers of West Michigan

GSK2857916 (DREAMM5) (GlaxoSmithKline Research)

As Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5